

[Supplementary online material](#)

**Clinical Assessment of Endothelial Function in Convalescent COVID-19 patients**

**Undergoing Multidisciplinary Pulmonary Rehabilitation.**

Pasquale Ambrosino, **MD PhD**<sup>1\*</sup> Antonio Molino, **MD**<sup>2\*</sup>

Ilenia Calcaterra, **MD**<sup>3</sup> Roberto Formisano, **MD**<sup>1</sup> Silvia Stufano, **PT**<sup>1</sup>

Giorgio Alfredo Spedicato, **PhD FCAS FSA CSPA CStat**<sup>4</sup> Andrea Motta, **PhD**<sup>5</sup>

Antimo Papa, **MD**<sup>1</sup> Matteo Nicola Dario Di Minno, **MD PhD**<sup>6\*\*</sup> Mauro Manisclaco, **MD PhD**<sup>1\*\*</sup>


\*The two Authors equally contributed to the manuscript.

\*\*The two Authors share co-seniorship.

**Table of contents**

<b>Supplemental Figure S1</b>	<b>Flow chart of study participants.</b>
<b>Supplemental Table S1</b>	<b>Pharmacological therapies and oxygen supplementation in convalescent COVID-19 patients undergoing pulmonary rehabilitation.</b>
<b>Supplemental Table S2</b>	<b>Impact of major clinical and demographic characteristics on changes in flow-mediated dilation (<math>\Delta</math>FMD) in convalescent COVID-19 patients undergoing pulmonary rehabilitation.</b>

**Supplementary Figure S1. Flow chart of study participants.**



**AMI: acute myocardial infarction; FMD: flow-mediated dilation; PR: pulmonary rehabilitation.**

\*2 patients withdrawn informed consent for personal reasons, 1 patient transferred for clinical reasons.

**Supplemental Table S1. Pharmacological therapies and oxygen supplementation in convalescent COVID-19 patients undergoing pulmonary rehabilitation.**

	Baseline N=82	After PR N=82	P values
Statins (%)	29.3	-	-
Oral Antidiabetics (%)	15.8	-	-
Insulin (%)	12.2	-	-
Allopurinol (%)	4.9	-	-
β-blockers (%)	23.2	-	-
ACE-I (%)	25.6	-	-
CCB (%)	8.5	-	-
ARB (%)	8.5	-	-
Diuretics (%)	15.8	-	-
Antiplatelet Drugs (%)	22.0	-	-
Oral Anticoagulants (%)	17.1	-	-
NSAIDs (%)	23.2	-	-
Corticosteroids (%)	62.2	56.1	0.525
Antibiotics (%)	22.0	3.7	<b>0.001</b>
LMWH (%)	54.9	23.2	<b>&lt;0.001</b>
O <sub>2</sub> at Rest (%)	31.7	12.2	<b>0.004</b>
O <sub>2</sub> Overnight (%)	26.8	12.2	<b>0.029</b>
O <sub>2</sub> During Exercise (%)	30.5	12.2	<b>0.007</b>

**N:** number; **PR:** pulmonary rehabilitation; **ACE-I:** angiotensin-converting enzyme inhibitors; **CCB:** calcium channel blockers; **ARB:** angiotensin II receptor blockers; **NSAIDs:** non-steroidal anti-inflammatory drugs; **LMWH:** low molecular weight heparin; **O<sub>2</sub>:** oxygen.

**Supplemental Table S2. Impact of major clinical and demographic characteristics on changes in flow-mediated dilation ( $\Delta$ FMD) in convalescent COVID-19 patients undergoing pulmonary rehabilitation.**

Independent variable	$\Delta$ FMD (presence vs. absence)	P value
Elderly ( $\geq 65$ years)	+2.20% $\pm$ 2.76 vs. +1.49% $\pm$ 1.91	0.174
Female gender	+1.84% $\pm$ 3.63 vs. +1.74% $\pm$ 1.99	0.899
Mechanical ventilation	+1.89% $\pm$ 1.57 vs. +1.72% $\pm$ 2.46	0.779
High-flow O <sub>2</sub>	+1.46% $\pm$ 1.80 vs. +1.87% $\pm$ 2.43	0.475
WHO class IV	+1.91% $\pm$ 2.51 vs. +1.49% $\pm$ 1.78	0.428
Hypertension	+1.65% $\pm$ 2.68 vs. +1.86% $\pm$ 1.89	0.682
Hypercholesterolemia	+2.54% $\pm$ 2.19 vs. +1.71% $\pm$ 2.29	0.434
Hypertriglyceridemia	+2.89% $\pm$ 2.85 vs. +1.71% $\pm$ 2.25	0.383
Diabetes mellitus	+2.29% $\pm$ 2.44 vs. +1.65% $\pm$ 2.25	0.335
Smoking	+1.47% $\pm$ 2.11 vs. +1.79% $\pm$ 2.31	0.710
Obesity	+1.24% $\pm$ 1.66 vs. +1.99% $\pm$ 2.48	0.171
Heart failure	+2.23% $\pm$ 3.21 vs. +1.73% $\pm$ 2.23	0.637
COPD	+1.33% $\pm$ 2.51 vs. +1.79% $\pm$ 2.27	0.634
History of malignancy	+0.77% $\pm$ 1.77 vs. +1.82% $\pm$ 2.30	0.321

**WHO: world health organization; O<sub>2</sub>: oxygen; COPD: chronic obstructive pulmonary disease.**